The report provides comprehensive information on the
therapeutics under development for Secondary Progressive Multiple Sclerosis
(SPMS), complete with analysis by stage of development, drug target, mechanism
of action (MoA), route of administration (RoA) and molecule type. The report
also covers the descriptive pharmacological action of the therapeutics, its
complete research and development history and latest news and press releases.
Additionally, the report provides an overview of key players involved in
therapeutic development for Secondary Progressive Multiple Sclerosis (SPMS) and
features dormant and discontinued projects.
Get Sample Report @ https://www.wiseguyreports.com/sample-request/619266-secondary-progressive-multiple-sclerosis-spms-pipeline-review-h2-2016
Report features investigational drugs from across globe
covering over 20 therapy areas and nearly 3,000 indications. Drug profiles
featured in the report undergoes periodic review following a stringent set of
processes to ensure that all the profiles are updated with the latest set of
information. Additionally, various dynamic tracking processes ensure that the
most recent developments are captured on a real time basis.
The report helps in identifying and tracking emerging
players in the market and their portfolios, enhances decision making
capabilities and helps to create effective counter strategies to gain
competitive advantage.
Scope
- The report provides a snapshot of the global therapeutic
landscape of Secondary Progressive Multiple Sclerosis (SPMS)
- The report reviews pipeline therapeutics for Secondary
Progressive Multiple Sclerosis (SPMS) by companies and universities/research
institutes based on information derived from company and industry-specific
sources
- The report covers pipeline products based on various
stages of development ranging from pre-registration till discovery and
undisclosed stages
- The report features descriptive drug profiles for the
pipeline products which includes, product description, descriptive MoA, R&D
brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Secondary
Progressive Multiple Sclerosis (SPMS) therapeutics and enlists all their major
and minor projects
- The report assesses Secondary Progressive Multiple
Sclerosis (SPMS) therapeutics based on drug target, mechanism of action (MoA),
route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued
pipeline projects
- The report reviews latest news related to pipeline
therapeutics for Secondary Progressive Multiple Sclerosis (SPMS)
Reasons to buy
- Gain strategically significant competitor information,
analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product
portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of
therapeutics under development for Secondary Progressive Multiple Sclerosis
(SPMS)
- Identify potential new clients or partners in the target
demographic
- Develop strategic initiatives by understanding the focus
areas of leading companies
- Plan mergers and acquisitions effectively by identifying
key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by
understanding Secondary Progressive Multiple Sclerosis (SPMS) pipeline depth
and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing
strategies by identifying prospective partners with the most attractive
projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying
discontinued projects and understanding the factors that drove them from
pipeline
Table of
Contents
Table of Contents 2
List of Tables 6
List of Figures 7
Introduction 8
Secondary Progressive Multiple Sclerosis (SPMS) Overview 9
Therapeutics Development 10
Pipeline Products for Secondary Progressive Multiple
Sclerosis (SPMS) - Overview 10
Secondary Progressive Multiple Sclerosis (SPMS) -
Therapeutics under Development by Companies 11
Secondary Progressive Multiple Sclerosis (SPMS) - Pipeline
Products Glance 13
Late Stage Products 13
Clinical Stage Products 14
Early Stage Products 15
Secondary Progressive Multiple Sclerosis (SPMS) - Products
under Development by Companies 16
Secondary Progressive Multiple Sclerosis (SPMS) - Companies
Involved in Therapeutics Development 17
AB Science SA 17
Actelion Ltd 18
Biogen, Inc. 19
F. Hoffmann-La Roche Ltd. 20
Genzyme Corporation 21
Glialogix, Inc. 22
Immune Response BioPharma, Inc. 23
Innate Immunotherapeutics Ltd 24
Kyorin Pharmaceutical Co., Ltd. 25
Mallinckrodt Plc 26
MedDay SA 27
MedImmune, LLC 28
Merck KGaA 29
Meta-IQ ApS 30
Novartis AG 31
Opexa Therapeutics, Inc. 32
Xenetic Biosciences (UK) Limited 33
Secondary Progressive Multiple Sclerosis (SPMS) -
Therapeutics Assessment 34
Assessment by Monotherapy Products 34
Assessment by Target 35
Assessment by Mechanism of Action 38
7Assessment by Route of Administration 41
Assessment by Molecule Type 43
Drug Profiles 45
biotin - Drug Profile 45
Product Description 45
Mechanism Of Action 45
R&D Progress 45
DC-TAB - Drug Profile 49
Product Description 49
Mechanism Of Action 49
R&D Progress 49
etomoxir - Drug Profile 50
Product Description 50
Mechanism Of Action 50
R&D Progress 50
GLX-1112 - Drug Profile 51
Product Description 51
Mechanism Of Action 51
R&D Progress 51
GZ-402668 - Drug Profile 52
Product Description 52
Mechanism Of Action 52
R&D Progress 52
IB-MS - Drug Profile 53
Product Description 53
Access Report @ https://www.wiseguyreports.com/reports/619266-secondary-progressive-multiple-sclerosis-spms-pipeline-review-h2-2016
Contact Info:
NORAH TRENT
Partner Relations
& Marketing Manager
Ph:
+1-646-845-9349 (US)
Ph: +44 208 133 9349 (UK)
Get
in touch:
LinkedIn:
www.linkedin.com/company/4828928
Twitter:
https://twitter.com/WiseGuyReports
Facebook: https://www.facebook.com/Wiseguyreports-1009007869213183/?fref=ts
No comments:
Post a Comment